Advertisement

Topics

'Triple' Screening for AAA, PAD, High BP Reduces Mortality

06:48 EDT 31 Aug 2017 | Medscape

Results of the VIVA trial show that a program of three screening tests--for abdominal aortic aneurysm, peripheral arterial disease, and hypertension--resulted in a significant reduction in all-cause mortality at 5 years.
Medscape Medical News

Original Article: 'Triple' Screening for AAA, PAD, High BP Reduces Mortality

NEXT ARTICLE

More From BioPortfolio on "'Triple' Screening for AAA, PAD, High BP Reduces Mortality"

Quick Search
Advertisement
 

Relevant Topic

Adempas (riociguat)
The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after ...